Anastrozole in the management of breast cancer

Expert Opinion on Pharmacotherapy

Volumn 3, Issue 9, 2002, Pages 1329-1339

  Nabholtz, Jean Marc ^a   Reese, David ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Anastrozole; Breast cancer; Clinical efficacy; Tamoxifen; Tolerability

Indexed keywords

ANASTROZOLE; AROMATASE; AROMATASE INHIBITOR; CIMETIDINE; ESTRADIOL; ESTROGEN RECEPTOR; LETROZOLE; MEGESTROL ACETATE; PHENAZONE; PLACEBO; PROGESTERONE RECEPTOR; TAMOXIFEN; WARFARIN;

ADVANCED CANCER; ARTICLE; ASTHENIA; BREAST CANCER; CANCER ADJUVANT THERAPY; CANCER GROWTH; CANCER HORMONE THERAPY; CANCER SURVIVAL; CEREBROVASCULAR ACCIDENT; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; COST EFFECTIVENESS ANALYSIS; DEPRESSION; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DRUG ABSORPTION; DRUG POTENCY; DRUG POTENTIATION; DRUG SELECTIVITY; DRUG STRUCTURE; DRUG TOLERABILITY; DRUG WITHDRAWAL; DYSPNEA; EDEMA; ENDOMETRIUM CANCER; FEMALE; FRACTURE; GASTROINTESTINAL DISEASE; HEADACHE; HEART INFARCTION; HOT FLUSH; HUMAN; LETHARGY; MULTICENTER STUDY; MUSCULOSKELETAL DISEASE; PAIN; PHASE 3 CLINICAL TRIAL; POSTMENOPAUSE; RANDOMIZED CONTROLLED TRIAL; STATISTICAL ANALYSIS; THROMBOEMBOLISM; VAGINA DISEASE; WEIGHT GAIN;

ANIMALS; BREAST NEOPLASMS; DISEASE MANAGEMENT; DRUG EVALUATION; FEMALE; HUMANS; NITRILES; SURVIVAL ANALYSIS; TRIAZOLES;

EID: 0036724315     PISSN: 14656566     EISSN: None     Source Type: Journal    
DOI: 10.1517/14656566.3.9.1329     Document Type: Article

References (45)

1. Top 5 cancers for females and males in the US
2. Cancer in the European Community and its Member States
3. Cancer statistics, 2001
4. Systemic therapy in breast cancer: Efficacy and cost utility
5. The control of breast cancer: The role of tamoxifen
6. Efficacy of tamoxifen as treatment of breast cancer
7. Tamoxifen for early breast cancer: An overview of the randomised trials
8. Use of tamoxifen for breast cancer: Twenty-eight years later
9. Metastatic breast cancer
10. A randomised trial comparing two doses of the new selective aromatase inhibitor ('Arimidex') with megestrol acetate in postmenopausal women with advanced breast cancer
11. A Phase III trial comparing anastrozole (1 and 10 mg), a potent and selective aromatase inhibitor, with megestrol acetate in postmenopausal women with advanced breast cancer
12. Anastrozole versus megestrol acetate in the treatment of postmenopausal women with advanced breast carcinoma. Results of a survival update based on a combined analysis of data from two mature Phase III trials
13. Anastrozole is superior to tamoxifen as first-line therapy in hormone receptor-positive advanced breast carcinoma
14. Anastrozole (Arimidex™) versus tamoxifen as first-line therapy for advanced breast cancer (ABC) in postmenopausal (PM) women - Combined analysis of two identically designed multicenter trials
15. Risks versus benefits in the clinical application of aromatase inhibitors
16. Use of aromatase inhibitors in the adjuvant treatment of breast cancer
17. The effects of neoadjuvant anastrozole (Arimidex™) on tumour volume in postmenopausal women with breast cancer: A randomized, double-blind, single-center study
18. New endocrine therapies for breast cancer
19. The preclinical pharmacology of 'Arimidex' (Anastrozole; ZD1033) - A potent selective aromatase inhibitor
20. Influence of anastrozole ('Arimidex'), a selective, non-steroidal aromatase inhibitor, on in vivo aromatization and plasma oestrogen levels in post-menopausal women with breast cancer
21. 'Arimidex' (ZD1033): A selective, potent inhibitor of aromatase in post-menopausal female volunteers
22. Arimidex™: A new, oral, once-a-day aromatase inhibitor
23. A randomized, open, parallel-group trial to compare the endocrine effects of oral anastrozole (Arimidex®) with intramuscular formestane in postmenopausal women with advanced breast cancer
24. Influence of neoadjuvant anastrozole (Arimidex™) on intratumoural estrogen levels and proliferation markers in patients with locally advanced breast cancer
25. Effects of the aromatase inhibitor anastrozole on serum oestrogens in Japanese and Caucasian women
26. Aromatase inhibitors and their use in the adjuvant setting
27. Arimidex®: A potent and selective fourth-generation aromatase inhibitor
28. Anastrozole: A review of its use in the management of postmenopausal women with advanced breast cancer
29. 'Arimidex' (anastrozole): Lack of interactions with tamoxifen, antipyrine, cimetidine and warfarin
30. The effect of anastrozole on the pharmacokinetics of tamoxifen in post-menopausal women with early breast cancer
31. Pharmacokinetics of anastrozole and tamoxifen alone, and in combination, during adjuvant endocrine therapy for early breast cancer in postmenopausal women: A sub-protocol of the 'Arimidex and tamoxifen alone (ATAC) trial
32. Assessment of response to therapy in advanced breast cancer
33. Anastrozole, a potent and selective aromatase inhibitor, versus megestrol acetate in postmenopausal women with advanced breast cancer: Results of overview analysis of two Phase III trials
34. Arimidex™ (anastrozole) - Effective in advanced breast cancer (ABC) patients with visceral and liver metastases
35. Static disease on anastrozole provides similar benefit as objective response in patients with advanced breast cancer
36. Critique of survival update analysis from two Phase III anastrozole clinical trials
37. Cost-effectiveness implications of increased survival in the treatment of advanced breast cancer
38. Letrozole (Femara) versus anastrozole (Arimidex): Second-line treatment in postmenopausal women with advanced breast cancer
39. Preliminary results of two comparative, multi-center clinical trials comparing the efficacy and tolerability of 'Arimidex' (anastrozole) and tamoxifen in postmenopausal women with advanced breast cancer
40. Anastrozole versus tamoxifen as first-line therapy for advanced breast cancer in 668 postmenopausal women: Results of the Tamoxifen or Arimidex Randomized Group Efficacy and Tolerability Study
41. Effects of neoadjuvant treatment with the aromatase inhibitor, anastrozole ('Arimidex') on peripheral and in situ estrogen synthesis and uptake by breast tissue in postmenopausal women
42. Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early breast cancer: First results of the ATAC randomised trial
43. Anastrozole: Data on side-effects from 1014 advanced breast cancer patients in four Phase III clinical trials
44. Superior efficacy of letrozole versus tamoxifen as first-line therapy for postmenopausal women with advanced breast cancer: Results of a Phase III study of the International Letrozole Breast Cancer Group